ACRXF cotización, noticias, gráficos, investigación bursátil, perfil.

 (ACRXF) Bolsa Cotizaciones y resumen de noticias

Acerinox SA is a Spain-based stainless steel maker engaged in the manufacture, processing, and marketing of stainless steel products and special alloys. The company operates in two segments; the Stainless steel segment which accounts for the majority of the company's revenue, includes both flat and long stainless steel products, and the High-performance alloys segment includes special alloys with high nickel content. This segment includes all the companies in the VDM Metals subgroup. Geographically the company operates in Spain, the Rest of Europe, America, Africa, Asia, and Others.

ACRXF

Los aranceles al acero afectan de manera desigual a ArcelorMittal y Acerinox. Descubre quién gana y quién pierde en este nuevo escenario.

ArcelorMittal vs. Acerinox: quién gana y quién pierde con los nuevos aranceles de Trump

CLLNY

PUIG BRANDS S.A. U/ADS by PUIG BRANDS S A

PUGBY

SYRVF

Descubre los valores del Ibex 35 con mayor potencial para 2025 y las estrategias clave detrás de sus recomendaciones.

5 valores del Ibex 35 que prometen un crecimiento del 40% o más en 2025

Acerinox SA

Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) shares are trading higher on Tuesday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46073683/carnival-corporation-plc-tops-guidance-achieving-highest-ever-second-quarter-operating-results-and" rel="noreferrer noopener">reported second-quarter results.</a>
The global cruise company reported adjusted earnings per share of 35 cents, beating the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of 24 cents. Quarterly sales of $6.328 billion outpaced the Street view of $6.207 billion.
The company reported adjusted EBITDA of $1.508 billion, compared with $1.197 billion a year ago.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45835785/cruise-wars-carnival-rides-momentum-while-norwegian-plays-the-long-game" rel="noreferrer noopener">Cruise Wars: Carnival Rides Momentum, While Norwegian Plays The Long Game</a>
&#8220;Close-in demand and onboard spending levels were incredibly strong for second-quarter sailings, and our booking curve continues to be the furthest out on record,&#8221;&nbsp;said CEO Josh Weinstein.
The company&#8217;s cumulative advanced booked position for the remainder of the year remains strong with occupancy the second-highest on record and pricing (in constant currency) at historical highs. While early, the company&#8217;s booked position for 2026 is in line with 2025 record levels (at the same time last year) and at historical high prices (in constant currency).
Operating margins and adjusted EBITDA margins&nbsp;increased over 500 and 300 basis points, respectively, compared to 2024 and significantly exceeded 2019 levels. Gross margin yields were over 25 percent higher than 2024.
Adjusted cruise costs excluding fuel per ALBD rose 3.5% from 2024, mainly due to more dry-dock days. Costs came in better than March guidance because some expenses shifted to later quarters.
&#8220;We have already exceeded our 2026 SEA Change financial targets a full 18 months early, increasing adjusted EBITDA per ALBD by 52% and more than doubling adjusted ROIC to over 12.5% in less than two years,&#8221; Weinstein added.
The company exited the quarter with cash and equivalents worth $2.146 billion, with inventories worth $476 million.
<h2 class="wp-block-heading">Outlook</h2>
The company is looking for&nbsp;third-quarter adjusted earnings per share of&nbsp;$1.30&nbsp;versus the $1.32&nbsp;analyst estimate. For the third quarter, the company expects net yields in constant currency to rise about 3.5% versus 2024 levels, which were up nearly 9%.
Carnival raises fiscal year 2025 adjusted earnings per share guidance&nbsp;from&nbsp;$1.83&nbsp;to&nbsp;$1.97&nbsp;versus the $1.89&nbsp;analyst estimate. For fiscal year 2025, the company expects net yields in constant currency to be about 5.0% higher than the year-ago period. This outlook is 0.3 percentage points above the March guidance.
For the remainder of 2025, newbuild capital expenditures are&nbsp;$1.1 billion&nbsp;and non-newbuild capital expenditures are&nbsp;$1.2 billion.
These future capital expenditures will fluctuate with foreign currency movements relative to the U.S. Dollar.&nbsp;
Price Action: CCL shares are trading higher by 10.1% to $26.46 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/46075307/td-synnex-q2-gross-billings-soar-double-digits" target="_blank" rel="noreferrer noopener">TD SYNNEX Q2 Gross Billings Soar Double Digits</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

News

Guidance

Markets

Movers

General

Carnival Sails Past Q2 Estimates, Raises Full-Year Outlook On Strong Demand

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is reportedly preparing for another round of layoffs with the majority of job cuts expected to impact <a href="https://www.benzinga.com/top-stories/25/05/45498574/microsoft-stock-nears-record-high-as-ai-driven-layoffs-hit-hundreds-even-ai-director">its sales division. </a>
The Details: The upcoming round of layoffs is part of a broader restructuring as the company ramps up its investment in artificial intelligence. The layoffs are anticipated to be announced in early July, aligning with the end of Microsoft's fiscal year, according to a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-06-18/microsoft-planning-thousands-more-job-cuts-aimed-at-salespeople?embedded-checkout=true">report</a>. 
Read Next: <a href="https://www.benzinga.com/markets/tech/25/06/45810135/walmart-microsoft-disney-slash-jobs-as-trump-tariffs-ai-push-corporate-america-into-layoff-mode">Walmart, Microsoft, Disney Slash Jobs As Trump Tariffs, AI Push Corporate America Into Layoff Mode</a>
The exact timing and affected departments could still change and while sales roles could be hit hardest, other areas may also see reductions.&nbsp;
This upcoming round follows a significant<a href="https://www.benzinga.com/markets/tech/25/06/45738506/microsoft-fires-hundreds-more-workers-amid-ai-fueled-growth-calls-it-positioning-the-company-for-success"> layoff in May</a>, when about 6,000 employees—roughly 3% of Microsoft's global workforce—were let go, mostly from product and engineering teams.&nbsp;
The company's latest restructuring reflects a shift in priorities, as Microsoft allocated $80 billion this year for capital expenditures to expand data centers and support its AI operations.
Following a separate round of layoffs in early June, a Microsoft representative <a href="https://www.benzinga.com/markets/tech/25/06/45738506/microsoft-fires-hundreds-more-workers-amid-ai-fueled-growth-calls-it-positioning-the-company-for-success">told</a> Bloomberg:&nbsp;
&#8220;We continue to implement organizational changes necessary to best position the company for success in a dynamic marketplace.&#8221;
Why It Matters: Several other major companies have recently made large job cuts, including Procter &amp; Gamble eliminating 7,000 jobs over two years and Walmart slashing 1,500 positions across its technology and e-commerce divisions.&nbsp;
Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) CEO Andy Jassy warned last week that generative AI and agentic AI will reduce the tech giant's total workforce in the next few years.
Read More:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46050532/mark-zuckerbergs-maga-pivot-driven-by-elon-musk-envy-image-goals-say-betrayed-meta-insiders-report">Mark Zuckerberg&#8217;s MAGA Pivot Driven By Elon Musk Envy, Image Goals, Say &#8216;Betrayed&#8217; Meta Insiders: Report</a></li>
</ul>
Image: Shutterstock

Large Cap

Tech

Trading Ideas

AMZN

MSFT

Microsoft's AI Gets $80 Billion—While Pink Slips Print By The Thousand

WIIM

LYFT

Lyft shares are trading higher after TD Cowen analyst John Blackledge upgraded the stock from Hold to Buy and raised the price target from $16 to $21.

Barclays analyst Luke Sergott maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Equal-Weight and raises the price target from $115 to $125.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Agilent Technologies, Raises Price Target to $125

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $77 price target.

Reiteration

CAPR

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target

When it comes to questions about the stock market, more often than not the correct answer is &#8220;I do not know.&#8221;
What will stocks do if we use a bunker buster in Iran?
I do not know.
Back during the lead-up to the first Gulf War, everyone just knew that the ground war would cause oil prices to explode higher and stocks to collapse. Once the first tank engine fired up, oil collapsed, and stock prices began climbing higher.
The consensus was that Barack Obama would be the worst thing that ever happened to the US stock market. The bear market of the Great Financial Crisis ended a few weeks after his inauguration.
Similarly, everyone was convinced that Donald Trump&#8217;s election in 2016 would lead to a massive market failure. It did not. The fear-driven selling in the overnight futures market was an epic buying opportunity.
On the morning of October 19, 1987, investors were afraid that we would see a market collapse and a 1930s-style depression and were dumping stocks. It was the dead-on bottom of the market. The market has never come anywhere near those prices again.
Everyone was sure that the downgrade of U.S. sovereign debt by S&amp;P in 2011 would spook investors, trigger rising bond yields, and push stocks into a tailspin. The S&amp;P 500 is up 6x since, while the QQQ is up 10-fold.
Opinions are prolific. With the internet, you apparently have gained the right to hear everyone&#8217;s opinion at high volume all the time. You will make a lot more money if you tune them all out and pay attention to value and trend.
One thing we do know for certain is that like everything else in the world, the price of stocks is set by supply and demand. If there is a rush to buy certain stocks, sellers will demand a higher price. We also know that rising prices attract attention and new buyers. There are a million logical reasons why this should not be the case, but there are a million and one behavioral reasons that it is true.
Finding that point where buyers begin to emerge and reverse the trend from negative to positive can lead to huge winners for investors.
Using the tools and ranking systems available at Benzinga Edge and Benzinga Pro, I looked at stocks that have been in a downturn and where bargain hunters have emerged. Thanks to that new source of buying pressure, the short-term trend has reversed higher. As the stock rises and triggers intermediate and long-term trend signals, more buying pressure will develop and could drive the stock a lot higher.
Here are three stocks that have established new short-term uptrends and could be on the verge of massive moves to the upside:
Infosys (Ticker: INFY)
Infosys is a global leader in digital services and consulting based in India, serving Fortune 500 clients across cloud, AI, and IT modernization. With a legacy of cost discipline and delivery excellence, Infosys remains a key player in the outsourcing landscape, though it faces margin pressures as clients delay discretionary spending.
Infosys is the Indian IT company that everyone makes fun of as they are writing checks to outsource tech services. They are moving aggressively into using AI for marketing and helping companies automate and become more efficient.
Infosys is also a big player in the Internet of Things, cloud computing and storage, as well as cybersecurity. As India works to develop closer ties to the United States, it could pay huge dividends for Infosys and its shareholders.
Healthcare Realty (Ticker: HR)
Healthcare Realty is a real estate investment trust (REIT) specializing in medical office buildings, primarily affiliated with hospital systems in growing Sun Belt and suburban markets. After its 2022 merger with Healthcare Trust of America, HR has been navigating elevated leverage and occupancy challenges, but its stable rent roll and long-term leases tied to healthcare demand offer defensive cash flow in a volatile REIT market.
I love real estate. Some of my biggest winners over the years have involved real estate and REITs. Medical office real estate should be a stable and growing market for a long time.
Healthcare Realty also owns a lot of outpatient facilities like surgical centers, labs, clinics, and rehab facilities. All in, the REIT has an occupancy rate of almost 90%. These shares are yielding about 8%, and it looks like institutional buyers are starting to move back into the shares.
Shark Ninja (Ticker: SN)
Shark Ninja is a consumer products company known for its high-performance home appliances under the Shark and Ninja brands, including vacuum cleaners, air fryers, and blenders. With a reputation for design-driven innovation and aggressive product launches, the company has carved out a strong market position but operates in a highly competitive and promotional retail environment that demands constant reinvention to maintain growth and pricing power.
I am married to a neat freak who perfectly offsets my somewhat casual attitude towards cleaning. She tried several brands of vacuum cleaners under the sun and was never quite satisfied until she found this brand. Now we have a Shark for indoors and an older one she uses outdoors on the patio and deck area.
Judging by the strong sales and earnings growth Shark Ninja is experiencing, she is not the only one who loves this brand.
Catching a trend change early can lead to huge gains. No opinions necessary. Just use the tools to follow the price.

Opinion

INFY

Under the Radar: No Forecasts, No Guesswork—Just the Trend

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Overweight and raises the price target from $12 to $13.

Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $13

<a href="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_06242025_LGVN_Sorensen.pdf" title="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_06242025_LGVN_Sorensen.pdf">https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_06242025_LGVN_Sorensen.pdf</a>

LGVN

Watching Longeveron; Zacks Small-Cap Research Gives Stock $9.55 Price Valuation

Leerink Partners analyst Andrew Berens maintains Nuvalent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) with a Outperform and raises the price target from $125 to $140.

NUVL

Leerink Partners Maintains Outperform on Nuvalent, Raises Price Target to $140

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Nuvalent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) with a Buy and raises the price target from $110 to $130.

HC Wainwright & Co. Maintains Buy on Nuvalent, Raises Price Target to $130

Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-06-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Culp will report an earnings per share (EPS) of $0.05.
Culp bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.09, which was followed by a 12.35% drop in the share price the next day.

<img src="https://www.benzinga.com/files/images/story/2025/1750777370_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Culp were trading at $3.78 as of June 23. Over the last 52-week period, shares are down 13.16%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CULP/earnings">To track all earnings releases for Culp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CULP

Culp Earnings Preview

Disclosed on June 23, CARY MCMILLAN, Director at Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: MCMILLAN's decision to sell 1,000 shares of Hyatt Hotels was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001468174/000146817425000079//Archives/edgar/data/1468174/000146817425000079/0001468174-25-000079-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total value of the sale is $132,700.
The latest market snapshot at Tuesday morning reveals Hyatt Hotels shares up by 0.17%, trading at $132.88.
<h3>Unveiling the Story Behind Hyatt Hotels</h3>
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.
<h3>Unraveling the Financial Story of Hyatt Hotels</h3>
Revenue Growth: Hyatt Hotels displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 0.23%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 19.32%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Hyatt Hotels exhibits below-average bottom-line performance with a current EPS of 0.2.
</li>
</ul>
Debt Management: Hyatt Hotels's debt-to-equity ratio is below the industry average at 1.33, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 16.77 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.0, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 9.45, Hyatt Hotels could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001468174">Check Out The Full List Of Hyatt Hotels's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

CARY MCMILLAN Takes Money Off The Table, Sells $132K In Hyatt Hotels Stock

On June 23, a substantial insider purchase was made by William F. Hulse as attorney-in-fact Dorothy Puhy, Board Member at MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>), as per the latest SEC filing.
What Happened: In a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001376339/000137633925000061//Archives/edgar/data/1376339/000137633925000061/0001376339-25-000061-index.htm">U.S. Securities and Exchange Commission</a>, it was disclosed that Puhy bought 28,609 shares of MiMedx Group, amounting to a total of $185,100.
Tracking the Tuesday's morning session, MiMedx Group shares are trading at $5.94, showing a down of 0.0%.
<h3>Unveiling the Story Behind MiMedx Group</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>Understanding the Numbers: MiMedx Group's Finances</h3>
Revenue Growth: MiMedx Group displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 4.13%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 81.23%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): MiMedx Group's EPS is below the industry average. The company faced challenges with a current EPS of 0.05. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: MiMedx Group's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 22.0 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 2.51 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 12.71, MiMedx Group demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001376339">Check Out The Full List Of MiMedx Group's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MDXG

Eye On Growth: William F. Hulse as attorney-in-fact Dorothy Puhy Adds $185K Of MiMedx Group Stock To Portfolio

A notable insider purchase on June 23, was reported by Tiffany Olson, Board Member at MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>), based on the most recent SEC filing.
What Happened: Olson made a significant move by purchasing 28,609 shares of MiMedx Group as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001376339/000137633925000064//Archives/edgar/data/1376339/000137633925000064/0001376339-25-000064-index.htm">U.S. Securities and Exchange Commission</a>. The transaction's total worth stands at $185,100.
MiMedx Group shares are trading down 0.0% at $5.94 at the time of this writing on Tuesday morning.
<h3>Delving into MiMedx Group's Background</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>MiMedx Group: A Financial Overview</h3>
Revenue Growth: MiMedx Group's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 4.13%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 81.23%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): MiMedx Group's EPS is below the industry average. The company faced challenges with a current EPS of 0.05. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: MiMedx Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 22.0 is lower than the industry average, implying a discounted valuation for MiMedx Group's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 2.51 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 12.71, MiMedx Group demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001376339">Check Out The Full List Of MiMedx Group's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bullish Move: Tiffany Olson Shows Confidence, Acquires $185K In MiMedx Group Stock

In a recent SEC filing, it was revealed that Cato T Laurencin, Director at MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>), made a noteworthy insider purchase on June 23,.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001376339/000137633925000066//Archives/edgar/data/1376339/000137633925000066/0001376339-25-000066-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Laurencin increased their investment in MiMedx Group by purchasing 28,609 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $185,100.
Tracking the Tuesday's morning session, MiMedx Group shares are trading at $5.94, showing a down of 0.0%.
<h3>Delving into MiMedx Group's Background</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>Key Indicators: MiMedx Group's Financial Health</h3>
Revenue Growth: MiMedx Group's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 4.13%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 81.23%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): MiMedx Group's EPS reflects a decline, falling below the industry average with a current EPS of 0.05.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 22.0, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.51, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 12.71, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Unlocking the Meaning of Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001376339">Check Out The Full List Of MiMedx Group's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Director Of MiMedx Group Makes $185K Buy

It was revealed in a recent SEC filing that William A Hawkins, Board Member at MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) made a noteworthy insider purchase on June 23,.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001376339/000137633925000068//Archives/edgar/data/1376339/000137633925000068/0001376339-25-000068-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Hawkins increased their investment in MiMedx Group by purchasing 28,609 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $185,100.
MiMedx Group's shares are actively trading at $5.94, experiencing a down of 0.0% during Tuesday's morning session.
<h3>Delving into MiMedx Group's Background</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>MiMedx Group's Economic Impact: An Analysis</h3>
Revenue Growth: MiMedx Group displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 4.13%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 81.23%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): MiMedx Group's EPS reflects a decline, falling below the industry average with a current EPS of 0.05.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.09, MiMedx Group adopts a prudent financial strategy, indicating a balanced approach to debt management.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: MiMedx Group's P/E ratio of 22.0 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 2.51, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): MiMedx Group's EV/EBITDA ratio of 12.71 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001376339">Check Out The Full List Of MiMedx Group's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Noteworthy Insider Activity: William A Hawkins Invests $185K In MiMedx Group Stock

A new SEC filing reveals that James L Bierman, Board Member at MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>), made a notable insider purchase on June 23,.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001376339/000137633925000070//Archives/edgar/data/1376339/000137633925000070/0001376339-25-000070-index.htm">U.S. Securities and Exchange Commission</a> on Monday unveiled that Bierman made a notable purchase of 28,609 shares of MiMedx Group, valuing at $185,100.
Monitoring the market, MiMedx Group's shares down by 0.0% at $5.94 during Tuesday's morning.
<h3>About MiMedx Group</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>MiMedx Group: A Financial Overview</h3>
Positive Revenue Trend: Examining MiMedx Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.13% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 81.23%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): MiMedx Group's EPS reflects a decline, falling below the industry average with a current EPS of 0.05.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.09, MiMedx Group adopts a prudent financial strategy, indicating a balanced approach to debt management.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 22.0 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 2.51 is lower than the industry average, implying a discounted valuation for MiMedx Group's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 12.71, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001376339">Check Out The Full List Of MiMedx Group's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Positive Signal: James L Bierman Shows Faith, Buying $185K In MiMedx Group Stock

In a recent SEC filing, it was revealed that William F. Hulse as attorney-in-factM. Kathleen Behrens Wilsey, Board Member at MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>), made a noteworthy insider purchase on June 23,.
What Happened: Wilsey's recent move, as outlined in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001376339/000137633925000072//Archives/edgar/data/1376339/000137633925000072/0001376339-25-000072-index.htm">U.S. Securities and Exchange Commission</a> on Monday, involves purchasing 28,609 shares of MiMedx Group. The total transaction value is $185,100.
Tracking the Tuesday's morning session, MiMedx Group shares are trading at $5.94, showing a down of 0.0%.
<h3>Discovering MiMedx Group: A Closer Look</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>MiMedx Group's Financial Performance</h3>
Revenue Growth: Over the 3 months period, MiMedx Group showcased positive performance, achieving a revenue growth rate of 4.13% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 81.23%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, MiMedx Group exhibits below-average bottom-line performance with a current EPS of 0.05.
</li>
</ul>
Debt Management: MiMedx Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 22.0 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 2.51 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 12.71 reflects market recognition of MiMedx Group's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001376339">Check Out The Full List Of MiMedx Group's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

William F. Hulse as attorney-in-factM. Kathleen Behrens Wilsey's Recent Buy: Acquires $185K In MiMedx Group Stock

<a href="https://www.ft.com/content/3d336a84-ac59-45ee-b857-8a01fc7cd806" title="https://www.ft.com/content/3d336a84-ac59-45ee-b857-8a01fc7cd806">https://www.ft.com/content/3d336a84-ac59-45ee-b857-8a01fc7cd806</a>

Macro Economic Events

Politics

Global

Economics

'EU Readies Retaliatory Tariffs To Secure Better Trade Deal With Trump; German Chancellor Backs More Muscular Approach Ahead Of July Talks Deadline' - Financial Times

A significant insider buy by Todd Newton, Board Member at MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>), was executed on June 23, and reported in the recent SEC filing.
What Happened: In a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001376339/000137633925000075//Archives/edgar/data/1376339/000137633925000075/0001376339-25-000075-index.htm">U.S. Securities and Exchange Commission</a>, it was disclosed that Newton bought 28,609 shares of MiMedx Group, amounting to a total of $185,100.
The latest market snapshot at Tuesday morning reveals MiMedx Group shares down by 0.0%, trading at $5.94.
<h3>Get to Know MiMedx Group Better</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>Breaking Down MiMedx Group's Financial Performance</h3>
Positive Revenue Trend: Examining MiMedx Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.13% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 81.23%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): MiMedx Group's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.05.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.09, MiMedx Group adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 22.0 is lower than the industry average, implying a discounted valuation for MiMedx Group's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 2.51 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 12.71, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001376339">Check Out The Full List Of MiMedx Group's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bullish Move: Todd Newton Shows Confidence, Acquires $185K In MiMedx Group Stock

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Discover the 10 best cryptocurrencies to invest in for January 2025. Stay ahead in the crypto market with our expert insights and analysis! Learn more now!

10 Best Cryptocurrencies to Invest In for June 2025

10 Best Cryptocurrencies to Invest in for January 2025

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Apertura	-
Cierre	-
Volumen / Prom.	- / -
Rango diario	- - -
Rango de 52 semanas	- - -
Capitalización bursátil	-
Ratio PER	-
Rentabilidad por dividendo	-
Exchange
RSI	0
Interés en corto	-
Días para cubrir	999.99

Apertura	-
Cierre	-
Volumen / Prom.	- / -
Rango diario	- - -
Rango de 52 semanas	- - -
Capitalización bursátil	-
Ratio PER	-
Rentabilidad por dividendo	-
Exchange
RSI	0
Interés en corto	-
Días para cubrir	999.99

Comments

(ACRXF) Previsión

(ACRXF) Bolsa Cotizaciones y resumen de noticias

Noticias recientes

Finanzas

Comparar

PREGUNTAS FRECUENTES

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Nombre

Ingresos Variación
Bruto Variación
EBITDA Variación
EBIT Variación
Beneficios Variación